Interaction between Eltrombopag and Zinc acetate
Moderate
Absorption
| ID | DDInter631 and DDInter1963 |
| Interaction | INTERVAL: Products containing aluminum, calcium, iron, magnesium, zinc and other polyvalent cations such as antacids or mineral supplements can significantly reduce the gastrointestinal absorption of eltrombopag due to chelation. |
| Management | Eltrombopag should be taken on an empty stomach at least 2 hours before or 4 hours after oral medications that contain antacids (e.g., didanosine buffered tablets or pediatric oral solution), aluminum, calcium, iron, magnesium, zinc or other polyvalent cations. |
| References | |
| Alternative for Eltrombopag |
B02B
Anti-inhibitor coagulant complex
Fostamatinib
Romiplostim
Avatrombopag
Epinephrine (ophthalmic)
Epinephrine (topical)
Coagulation factor VIIa Recombinant Human
Epinephrine
Phylloquinone
Coagulation factor X human
Emicizumab
More
|
| Alternative for Zinc acetate |
C05A
Triamcinolone (topical)
Triamcinolone
Betamethasone (topical)
Triamcinolone (nasal)
Prednisolone (ophthalmic)
Procaine
More
|
Potential Metabolism Interactions
Substrate-Substrate Interaction：If more than one drug is metabolized by the same CYP, it is possible that its metabolism is inhibited because of the competition between the drugs. That means, it can be useful to lower the dosage of the drugs in the drug-cocktail because they remain longer in the organism than in monotherapy.
Inhibitor-Inhibitor Interaction：Combining two or more inhibitors of one CYP, should be compensated by lowering the dosage of these drugs because the metabolism is reduced and the drugs remain longer in the organism than in monotherapy. Not adapting the dosage bears the risk of even more side effects.
Inhibitor-Substrate Interaction：Combining drugs that have inhibitory effect and are substrates of one particular CYP, should be compensated by lowering the dosage. They rest longer in the organism than in monotherapy. Not adapting the dosage bears the risk of even more side effects.